OBJECTIVES: To compare the impact of two probiotic supplements on fecal microbiota and metabolites, as well as on gut inflammation in human milk-fed preterm infants. METHODS: In this single-center observational cohort study, we assessed the effects of Bifidobacterium longum subsp. infantis or Lactobacillus reuteri supplementation on the infant gut microbiota by 16S rRNA gene sequencing and fecal metabolome by 1 H nuclear magnetic resonance spectroscopy. Fecal calprotectin was measured as a marker of enteric inflammation. Aliquots of human or donor milk provided to each infant were also assessed to determine human milk oligosaccharide (HMO) content. RESULTS: As expected, each probiotic treatment was associated with increased proportions of the respective bacterial taxon. Fecal HMOs were significantly higher in L. reuteri fed babies despite similar HMO content in the milk consumed. Fecal metabolites associated with bifidobacteria fermentation products were significantly increased in B. infantis supplemented infants. Fecal calprotectin was lower in infants receiving B. infantis relative to L. reuteri ( P < 0.01, Wilcoxon rank-sum test) and was negatively associated with the microbial metabolite indole-3-lactate (ILA). CONCLUSIONS: This study demonstrates that supplementing an HMO-catabolizing Bifidobacterium probiotic results in increased microbial metabolism of milk oligosaccharides and reduced intestinal inflammation relative to a noncatabolizing Lactobacillus probiotic in human milk-fed preterm infants. In this context, Bifidobacterium may provide greater benefit in human milk-fed infants via activation of the microbiota-metabolite-immune axis.
OBJECTIVES: To compare the impact of two probiotic supplements on fecal microbiota and metabolites, as well as on gut inflammation in human milk-fed preterm infants. METHODS: In this single-center observational cohort study, we assessed the effects of Bifidobacterium longum subsp. infantis or Lactobacillus reuteri supplementation on the infant gut microbiota by 16S rRNA gene sequencing and fecal metabolome by 1 H nuclear magnetic resonance spectroscopy. Fecal calprotectin was measured as a marker of enteric inflammation. Aliquots of human or donor milk provided to each infant were also assessed to determine human milk oligosaccharide (HMO) content. RESULTS: As expected, each probiotic treatment was associated with increased proportions of the respective bacterial taxon. Fecal HMOs were significantly higher in L. reuteri fed babies despite similar HMO content in the milk consumed. Fecal metabolites associated with bifidobacteria fermentation products were significantly increased in B. infantis supplemented infants. Fecal calprotectin was lower in infants receiving B. infantis relative to L. reuteri ( P < 0.01, Wilcoxon rank-sum test) and was negatively associated with the microbial metabolite indole-3-lactate (ILA). CONCLUSIONS: This study demonstrates that supplementing an HMO-catabolizing Bifidobacterium probiotic results in increased microbial metabolism of milk oligosaccharides and reduced intestinal inflammation relative to a noncatabolizing Lactobacillus probiotic in human milk-fed preterm infants. In this context, Bifidobacterium may provide greater benefit in human milk-fed infants via activation of the microbiota-metabolite-immune axis.
Authors: John Penders; Carel Thijs; Cornelis Vink; Foekje F Stelma; Bianca Snijders; Ischa Kummeling; Piet A van den Brandt; Ellen E Stobberingh Journal: Pediatrics Date: 2006-08 Impact factor: 7.124
Authors: Marie-Claire Arrieta; Leah T Stiemsma; Pedro A Dimitriu; Lisa Thorson; Shannon Russell; Sophie Yurist-Doutsch; Boris Kuzeljevic; Matthew J Gold; Heidi M Britton; Diana L Lefebvre; Padmaja Subbarao; Piush Mandhane; Allan Becker; Kelly M McNagny; Malcolm R Sears; Tobias Kollmann; William W Mohn; Stuart E Turvey; B Brett Finlay Journal: Sci Transl Med Date: 2015-09-30 Impact factor: 17.956
Authors: Chris H P van den Akker; Johannes B van Goudoever; Raanan Shamir; Magnus Domellöf; Nicholas D Embleton; Iva Hojsak; Alexandre Lapillonne; Walter A Mihatsch; Roberto Berni Canani; Jiri Bronsky; Cristina Campoy; Mary S Fewtrell; Nataša Fidler Mis; Alfredo Guarino; Jessie M Hulst; Flavia Indrio; Sanja Kolaček; Rok Orel; Yvan Vandenplas; Zvi Weizman; Hania Szajewska Journal: J Pediatr Gastroenterol Nutr Date: 2020-05 Impact factor: 2.839
Authors: Catherine A Lozupone; Merete Eggesbø; Maggie A Stanislawski; Dana Dabelea; Brandie D Wagner; Nina Iszatt; Cecilie Dahl; Marci K Sontag; Rob Knight Journal: mBio Date: 2018-10-23 Impact factor: 7.867